18 and older, any sex, with Hypertension or Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or StrokePrimary· Index to 14 months post index
Ten year cardiovascular risk was calculated at each post index visit from the most recent clinical and laboratory values in the EMR. The Framingham lipid equation was used when a lipid value was available in the previous 5 years; otherwise the Framingham BMI equation was used. The primary outcome was the annualized rate of change (slope) in 10-year CVR, estimated for each treatment group from the time and time-by-treatment parameters of a mixed regression model which predicted post-index CVR values from time elapsed since index, treatment group and the time by treatment interaction.
Group
Value
95% CI
Prioritized Clinical Decision Support
-0.59
-1.43 – 0.26
Usual Care
1.66
0.81 – 2.52
Adverse events — posted to ClinicalTrials.gov
Time frame: We monitored rates of occurrence by study arm (blinded by study arm) every 6 months, from 6 months pre, through the end of the 24-month intervention period. Randomization occurred at the clinic level and all providers at the clinics had access to the CDS tool. We monitored all patients receiving care at randomized clinics regardless of their exposure to the intervention..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The objective of this project is to develop and implement sophisticated point-of-care Electronic Health Record (EHR)-based clinical decision support that (a) identifies and (b) prioritizes all available evidence-based treatment options to reduce a given patient's cardiovascular risk (CVR). After developing the EHR-based decision support intervention, the investigators will test its impact on CVR, the components of CVR, in a group randomized trial that includes 18 primary care clinics, 60 primary care physicians, and 18,000 adults with moderate or high CVR. This approach, if successful, will (a) improve chronic disease outcomes and reduce CVR for about 35% of the U.S. adult population, (b) maximize the clinical return on the massive investments that are increasingly being made in sophisticated outpatient EHR systems, and (c) provide a model for how to use EHR technology support to deliver "personalized medicine" in primary care settings
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Prioritized Clinical Decision Support
Trials testing the same drug.
NCT02451670 — Reducing Cardiovascular Risk in Adults With Serious Mental Illness
· NA
· completed
Other recruiting trials for Hypertension
Currently open trials in the same condition.
NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A
· NA
· recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S
· recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
· NA
· recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
· Phase 2
· recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension
· NA
· recruiting
Other HealthPartners Institute trials
Trials by the same sponsor.
NCT07127133 — An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzhei
· NA
· not yet recruiting
NCT07354919 — Axelopran in Advanced Cancers
· Phase 2
· not yet recruiting
NCT06434038 — Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age
· Phase 1
· withdrawn
NCT06914726 — Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
· NA
· enrolling by invitation
NCT06999330 — TMS in Anxiety-Parkinson's Disease
· NA
· enrolling by invitation
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HealthPartners Institute
Last refreshed: 21 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01420016.